Over 90 Total Lots Up For Auction at One Location - WA 04/08

Radiation Dosage Based on Body Mass Index Could Be Next Step for Personalized Medicine

by Barbara Kram, Editor | June 18, 2008
Radiation doses for cancer
patients rely on BMI
NEW ORLEANS, La.-In a new study, technologists are using body mass index (BMI), instead of body weight, to provide patients optimal dosing of 18-fluoro-2-deoxyglucose (FDG), a radiopharmaceutical commonly used in oncology imaging. BMI is a calculation that takes into account both a patient's weight and height. Traditionally, only a patient's weight has been taken into consideration when prescribing appropriate dosage of radiopharmaceuticals for positron emission tomography (PET) and computed tomography (CT) scans.

"Using BMI allows us to more specifically adjust dosing to individual patients," said Sarah Krumrey, a technologist in the Department of Nuclear Medicine at St. Louis University Hospital, St. Louis, Mo., and lead author of the study, Should FDG Dose Be Based on BMI Instead of Body Weight?, presented at SNM's 55th Annual Meeting, June 14-18 in New Orleans.

Current procedures for PET/CT scans with FDG use a patient's weight as the main factor in determining the appropriate dose. The goal of this study was to compare changes in PET/CT image quality as a result of switching from a weight-adjusted to a BMI-adjusted FDG dose. A BMI-adjusted dose was used in a total of a 104 patients undergoing PET/CT exams for known or suspected cancer. In this double-blinded study, PET/CT scans were reviewed and graded to access the image quality. Switching to a BMI-adjusted dose resulted in improved image quality and lower required dosage of 18-FDG.

"Based on our study, we believe that adjusting the FDG dose according to a patient's BMI could lead to new imaging protocols," added Krumrey. "We conclude that using a BMI-adjusted FDG dose instead of a weight-adjusted dose may help reduce radiation dose to patients and technologists without compromising PET/CT image quality."

Scientific Paper 2010: S.A. Krumrey, I. Tran, P. Yost, D. Oliver, N. Nhuyen, F. Qazi, Nuclear Medicine, M.M. Osman, St. Louis University Hospital, St. Louis, Mo.: "Should FDG Dose Be Based on BMI Instead of Body Weight?"

About SNM-Advancing Molecular Imaging and Therapy
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best healthcare possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.

SNM's more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings, and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org.

Back to HCB News